An experimental therapy trial was conducted at our facility using Gong Ming Anti-HIV (GMA-HIV) Intravenous Injection Liquid and Capsules for the treatment of AIDS during the periods of 1998 to 1999.

5ml of GMA-HIV Intravenous Injection Liquid mixed with 250ml of 5% Glucose or Saline solution applied intravenously once per day

6 capsules of GMA-HIV capsules, 3 times per day before meals.

Each treatment period is 3 months

During the 1st 2 weeks of treatment, all patients experienced stomach and costolateral pains. Patient 5 experienced vomiting every morning for a week during the 3rd month of treatment.

All patients exhibited psychological and physiological improvements after 1 month of treatment.

Patient 4 and 5 experienced a weight gain of 5kg. Patients 2 and 4 managed to kick their drug addiction. The various viral and bacteria infections mentioned above has had a normalized biochemical indication in most cases after treatment. CMV M antibody, Gonorrhea antibody and Hepatitis C antibody were undetectable after treatment.

Patient 1 and 5 continued with the treatment after the 1st treatment period. During the 2nd treatment period, no noticeable side-effects were observed. However after the 2nd treatment period, one patient’s CD4 count dropped to 440/mm3 while the other dropped to 606/mm3. Both patients however were always in a highly agitated psychological state due to family pressure and the loss of employment.

Patients were monitored after the treatment, physical health and mood were normal. There seem to be some improvements to their immune system as during the fall and winter months, when infectious diseases like flu and cold ran rampant, most of the patients did not get infected with the flu or the cold although a sustained normal CD4 count is not observed.

6 to 8 months after treatment, all the patients requested for more treatment. Due to the fact that all patients could not afford any of the current medication, it can be safely concluded that the patients did not undergo any treatments during the 6-8 months after the first treatment period. This brings up the question of how long is the effective period of GMA-HIV as these patients were still quite healthy despite a lack of treatment 6 to 8 months after the initial GMA-HIV treatment period. The question of whether there is a need to use GMA-HIV as part of a combination treatment with the current available antiretroviral drugs such as, AZT, ddI, A3T, etc., is still unclear as we did not test the before and after treatment HIV viral load in any of the patients. We also do not know if increasing the dosage of GMA-HIV will have increased effects on the control of viral loads and CD4 count.

We also observed a patient who was not included in this trial using a dosage of 15-20ml of GMA-HIV intravenous injection liquid experiencing chills and body temperature increase to 38° to 39°C. This high body temperature was sustained for 5 to 7 days. If HIV does not have any drug resistance or tolerance to GMA-HIV, we should determine at what dosage (including lethal dosage) and length of treatment period (not 3 months) to be used as a combination treatment with the current available antiretroviral drugs.